---
figid: PMC8166543__nmaa143fig4
figtitle: Promising Effects of Astaxanthin on Lung Diseases
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8166543
filename: nmaa143fig4.jpg
figlink: /pmc/articles/PMC8166543/figure/fig4/
number: F4
caption: The suggested molecular mechanisms of action for ASX in the prevention of
  lung diseases. ASX activates the Nrf–HO-1 pathway to inhibit emphysema and COPD
  and asthma development. ASX suppresses the NF-κB, MAPK, JAK/STAT-3, PI3K/Akt pathways.
  ASX downregulates Th1-mediated immune responses to alleviate asthma. ASX inhibits
  acute lung injury through its effect on the NF-κB and JAK/STAT-3 pathways; alleviates
  lung fibrosis by suppressing the NF-κB and MAPK pathways and NSCLC by ASX supplementation
  via the inhibited MAPK and PI3K/Akt pathways. ASX, astaxanthin; COPD, chronic obstructive
  pulmonary disease; JAK/STAT-3, Janus kinase–signal transducers and activators of
  transcription-3; MAPK, mitogen-activated protein kinase; Nrf-HO1, nuclear respiratory
  factor-2/heme oxygenase 1; NSCLC, non–small cell lung cancer; PI3K, phosphoinositide
  3-kinase; Th1, T helper type 1.
papertitle: The Promising Effects of Astaxanthin on Lung Diseases.
reftext: Junrui Cheng, et al. Adv Nutr. 2021 May;12(3):850-864.
year: '2021'
doi: 10.1093/advances/nmaa143
journal_title: Advances in Nutrition
journal_nlm_ta: Adv Nutr
publisher_name: Oxford University Press
keywords: astaxanthin | lung diseases | oxidative stress | molecular mechanism | lung
  cancer
automl_pathway: 0.9118814
figid_alias: PMC8166543__F4
figtype: Figure
redirect_from: /figures/PMC8166543__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8166543__nmaa143fig4.html
  '@type': Dataset
  description: The suggested molecular mechanisms of action for ASX in the prevention
    of lung diseases. ASX activates the Nrf–HO-1 pathway to inhibit emphysema and
    COPD and asthma development. ASX suppresses the NF-κB, MAPK, JAK/STAT-3, PI3K/Akt
    pathways. ASX downregulates Th1-mediated immune responses to alleviate asthma.
    ASX inhibits acute lung injury through its effect on the NF-κB and JAK/STAT-3
    pathways; alleviates lung fibrosis by suppressing the NF-κB and MAPK pathways
    and NSCLC by ASX supplementation via the inhibited MAPK and PI3K/Akt pathways.
    ASX, astaxanthin; COPD, chronic obstructive pulmonary disease; JAK/STAT-3, Janus
    kinase–signal transducers and activators of transcription-3; MAPK, mitogen-activated
    protein kinase; Nrf-HO1, nuclear respiratory factor-2/heme oxygenase 1; NSCLC,
    non–small cell lung cancer; PI3K, phosphoinositide 3-kinase; Th1, T helper type
    1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TH1
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Dif
  - dl
  - Rel
  - MKP-4
  - p38b
  - rl
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - hop
  - bsk
  - Akt
  - NELFCD
  - COPD
  - ARCN1
  - NFKB1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - STAT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - AKT1
  - AKT2
  - AKT3
---
